

BMJ Open

Can HIV reverse transcriptase activity assay be a low cost alternative for viral load monitoring in resource-limited settings?

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2015-008795
Article Type:	Research
Date Submitted by the Author:	28-May-2015
Complete List of Authors:	Gupta, Soham; St. John's Medical College, Microbiology Palchaudhuri, Riya; St. John's Medical College, Microbiology Neogi, Ujjwal; Karolinska Institutet, Laboratory Medicine Srinivasa, Hiresave; St. John's Medical College, Microbiology Ashorn, Per; University of Tampere School of Medicine, International Health de Costa, Ayesha; Karolinska Institutet, Department of Public Health Sciences Källander, Clas; Cavid AB, Research and Development Shet, Anita; St John's Medical College Hospital, Pediatrics
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	HIV/AIDS, Infectious diseases
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Diagnostic microbiology < INFECTIOUS DISEASES, Molecular diagnostics < INFECTIOUS DISEASES, Infection control < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts

1
2
3 **Can HIV reverse transcriptase activity assay be a low cost alternative for viral**
4 **load monitoring in resource-limited settings?**
5

6 Soham Gupta^{1*}, Riya Palchadhuri¹, Ujjwal Neogi^{2*}, Hiresave Srinivasa¹, Per Ashorn³,
7 Ayesha De Costa⁴, Clas Källander⁵, Anita Shet⁶
8

9 ¹Division of Clinical Virology, Department of Microbiology, St. John's medical
10 College, Bangalore, India

11 ²Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska
12 Institutet, Stockholm, Sweden.

13 ³Department for International Health, University of Tampere School of Medicine,
14 Finland

15 ⁴Department of Public Health Sciences, Karolinska Institute, Stockholm, Sweden

16 ⁵Cavidi AB, Uppsala, Sweden

17 ⁶Department of Pediatrics, St John's Medical College Hospital, Bangalore, India
18
19
20
21
22
23
24

25 ***Corresponding Author:**

26 E-mail: soham.micro@gmail.com (SG); ujjwal.neogi@ki.se (UN)
27
28
29
30

31 **Running Title:** Low cost HIV viral load monitoring
32
33
34

35 **Word Count:** 3471
36
37
38

39 **Key Words:** HIV-1 viral load monitoring; HIV reverse transcriptase activity assay;
40 Real time PCR; Resource-limited settings
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: To evaluate the performance and cost of an HIV reverse transcriptase-enzyme activity (HIV-RT) assay in comparison to a HIV-1 RNA assay for routine viral load monitoring in resource limited settings.

Design: Cohort based longitudinal study.

Setting: Two antiretroviral therapy (ART) centers in Karnataka state, South India, providing treatment under the Indian AIDS control program

Participants: Cohort of 327 HIV-1 infected Indian adult patients initiating first-line ART.

Outcome measures: The performance and cost of an HIV-RT assay (ExaVir Load v3) in comparison to a gold standard HIV-1 RNA assay (Abbott m2000rt) in a cohort of 327 Indian patients before (WK00) and 4 weeks (WK04) after initiation of first-line therapy.

Results: Plasma viral load was determined by HIV-1 RNA assay and HIV-RT assay in 629 samples (302 paired samples and 25 single time-point samples at WK00) obtained from 327 patients. Overall, a strong correlation of $r=0.96$ was observed, with good correlation at WK00 ($r = 0.84$) and at WK04 ($r = 0.77$). Bland-Altman analysis of all samples showed a good level of agreement with a mean difference (bias) of 0.22 \log_{10} copies/mL. The performance of ExaVir Load v3 was not negatively affected by a nevirapine/efavirenz based anti-retroviral regimen. The per test cost of measuring plasma viral load by Abbott m2000rt and ExaVir Load v3 assay in our setting was \$36.4 and \$17.3 respectively.

Conclusions: The strong correlation between HIV-RT and HIV-1 RNA assay suggests that the HIV-RT assay can be an affordable alternative option for monitoring patients on anti-retroviral therapy in resource-limited settings.

Strengths and Limitations of this study:

- To our knowledge the current study is the most thoroughly evaluated study of ExaVir Load v3 (HIV-RT assay) from India to date.
- This study was performed in a large number of subjects in a longitudinal manner looking into the effects of the NNRTI based therapy and drug resistance mutations on the performance of the HIV RT-enzyme activity assay.
- Though the assay has been validated before in other non-C subtype settings, in the present study the HIV-RT assay was validated on a larger scale in a subtype C predominant setting and subtype C is the most predominant subtype globally, more so affecting the resource limited settings.
- This study was limited to patients hailing from Southern India and a performance evaluation and cost-effectiveness of the HIV-RT assay needs to be accessed on a national level.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

The principle aim of anti-retroviral therapy (ART) is durable suppression of replicating plasma virus to undetectable levels, thereby delaying disease progression and prolonging survival.[1 2] Expanding access to ART in resource-limited settings along with close monitoring is needed for successful treatment outcomes. In high income settings this is achieved by performing quantitative viral load monitoring every 3-6 months,[3] as viral load monitoring detects early treatment failure. However in resource-limited settings therapeutic outcome is evaluated based on either CD4 T cell count or on clinical findings,[4] neither of which accurately predicts viral suppression.[5] Early detection of viral-failure by monitoring viral load also provides the opportunity to intensify adherence counseling to improve adherence to ART potentially leading to re-suppression of viral load before the evolution of drug resistant virus can take place.[6]

The currently used viral load assays are based on the amplification of HIV-1 virion RNA, which is considered impractical for wide-scale use in resource-limited settings, as it requires infrastructure, facilities for molecular diagnostics, expensive equipment and skilled technicians which are often unavailable.[7] Simpler, less expensive viral load assays would be very useful in the resource-limited environments that are most impacted by this epidemic.

An alternative to measure the HIV-1 RNA is to measure the activity of the viral reverse transcriptase (RT) enzyme. ExaVir Load assay (Cavidi, AB, Sweden), a low-cost and technically less-demanding assay using an enzyme linked immune sorbent assay (ELISA)-based method to measure RT enzyme activity has shown promising results.[8-19] Although previous versions of the test have been evaluated against several polymerase chain reaction (PCR)-based HIV tests that measure viral RNA, there are few comparative studies between ExaVir Load version 3 (v3) and such molecular real time assays.[14 16 18] The most recent version 3 of the ExaVir Load assay has an enhanced sensitivity (lower detection limit 200 copies/mL) and reduced turnaround time compared to version 2.[14 18]

HIV-1 subtype C (HIV-1C) is the dominant strain in most low middle-income countries like India, South Africa and Ethiopia [20] and the need for a simple low cost viral load monitoring tool is a priority in these settings. Data available from countries

1
2
3 dominated by the HIV-1C epidemic are limited. Where available, evaluations have
4 been mainly performed with earlier version assays (ExaVir Load v1 and v2), which
5 had lower detection limits of 400 copies/mL.[7 11 21 22] Studies evaluating ExaVir
6 Load v3 have been mainly performed in non-C dominated countries.[14 16 18 19]
7
8

9
10 Thus, we aimed to evaluate the performance of the HIV RT-enzyme activity (HIV RT)
11 assay (ExaVir Load v3) in comparison to a “gold standard” HIV RNA load (Abbott
12 m2000rt real-time PCR) assay in a cohort of patients before and after initiation of first-
13 line ART in Indian settings. We also compared viral load measurements from both
14 assays in a subset of patients with drug resistant mutations at baseline. Further, we
15 studied the difference in costs of the two viral load assays in the context of our
16 laboratory setting.
17
18
19
20
21
22
23
24

25 **Materials and Methods**

26 *Study participants and samples*

27
28
29
30 Between April 2010 and September 2011, EDTA plasma samples were collected from
31 HIV-1 infected adult patients attending Infectious Disease Clinic, St. John’s Medical
32 College and Hospital, Bangalore (main site) and ART center, Krishna Rajendra
33 Hospital, Mysore (peripheral site) enrolled in the HIVIND randomized controlled trial
34 (Trial registration: ISRCTN79261738).[23] All the patients included in the study
35 initiated ART with reverse transcriptase inhibitor (RTI) drugs, i.e. two nucleoside
36 reverse transcriptase inhibitors (NRTI), zidovudine (AZT) or stavudine (d4T) with
37 lamivudine (3TC) + one non-nucleoside reverse transcriptase inhibitors (NNRTI),
38 either Nevirapine (NVP) or Efavirenz (EFV) as per the standard national AIDS
39 program guidelines.[24]
40
41
42
43
44
45
46
47

48 Plasma samples were collected at two time points; (i) prior to ART initiation (not
49 longer than 3 months prior) and (ii) 4 weeks after ART initiation. The plasma samples
50 were separated within 6 hours of EDTA whole blood collection, aliquoted and stored at
51 -80°C in the main site. Plasma samples aliquoted in the peripheral site were stored at -
52 20°C and were transported to the main site on dry ice (every 2 weeks) and then stored
53 at -80°C prior to testing.
54
55
56
57
58
59
60

Ethical statement

Ethical approvals for the conduct of the trial were obtained from Institutional Ethical Review Board of St John's Medical College Hospital, Bangalore (IERB 1/369/08–92/2008) and Krishna Rajendra Hospital, Mysore (NO/PS/173/2010). All patients participating in the HIVIND study have given their written consent.

Plasma HIV-1 RNA assay

Plasma HIV-1 RNA load was measured in the patient cohort using Abbott Real Time PCR, m2000rt system with manual RNA extraction procedure on m2000sp sample preparation system as per the manufacturer's instructions. The assay was performed using an initial volume of 0.2 mL plasma, which provides limits of quantification between 150 copies/mL (lower limit of detection) to 10,000,000 copies/mL (upper limit of detection). In every run a negative control, a low positive control and a high positive control supplied in the Abbott Realtime HIV-1 control kit were included. This measure using Real Time PCR was considered as the gold standard. This protocol was validated by an external quality control program by the Quality Control for Molecular Diagnostics, Glasgow, Scotland (QCMD, <http://www.qcmd.gov>) on 2010 panel (Consisting of four HIV-1B samples, two HIV-1C samples, one HIV-1A/G sample and one HIV-1 negative sample) and obtained highly satisfactory score.

Plasma HIV RT enzyme activity assay

The viral RT enzyme activity was quantified using Cavid ExaVir Load v3 as per the instructions of the manufacturer [14]. In an ELISA based format, the RT activity of the RT enzyme recovered from 1mL of patient plasma was determined and compared to a standard curve based on known amounts of a HIV 1 recombinant RT constructed from the BH10 isolate. The RT activity in the sample was expressed as femtogram HIV-1 RT activity/mL (fg/mL) plasma that was translated into RNA copies/mL equivalent by the ExaVir Load analyzer software. The lower detection limit of the assay was $\geq 1\text{fg/mL}$ i.e. $\geq 200\text{copies/mL}$. In every run a single positive control and a negative control were used to monitor the performance of the RT extraction process and to

1
2
3 access between run variations. The positive control was prepared by pooling the EDTA
4 plasma from a high HIV-1 viral load sample and HIV-1 negative plasma; 1.2mL was
5 aliquoted and stored in -80°C freezer. The laboratory personnel running the ExaVir
6 Load v3 assay were blind to the plasma HIV-1 RNA values.
7
8
9

10 11 12 ***HIV-1 subtyping and baseline drug resistance*** 13

14
15 Genotypic resistance testing (GRT) was performed on the baseline plasma samples.
16 Briefly, the reverse transcriptase (RT) region of the HIV-1 *pol* gene was amplified and
17 sequenced using the primers described by us previously.[25] HIV-1 subtyping was
18 determined based on the *pol* gene as well as the *env* gene (wherever sequence data was
19 available).[26-28] using the maximum likelihood (ML) phylogenetic tree based on
20 reference sequences downloaded from Los Alamos Database (www.hiv.lanl.gov).
21 Primary drug resistance analysis was evaluated using World Health Organization list
22 of mutations from 2009 (WHO_SDRM 2009).[29]
23
24
25
26
27
28
29
30
31

32 ***Comparative cost analysis*** 33

34 Components used for cost comparison included costs for instruments and start-up kits,
35 human resource costs, annual maintenance, operator-supplied basic instruments,
36 reagents and other consumables for a period of 5 years time. The costs were compared
37 based on patient numbers in the ART Center of our hospital. There are at present, 1500
38 ART-experienced patients in our ART center. Assuming that viral load monitoring of
39 these patients will require to be performed every six months, there will be 3000
40 samples a year.
41
42
43
44
45

46 For HIV-1 RNA load by Abbott m2000rt, assays were done in a batch of 24 reactions,
47 each batch comprising 21 samples and 3 controls. Calibration of the HIV-1
48 amplification kits was performed once for every 5 kits of the same lot. Reagent costs
49 were calculated based on this degree of usage. In the HIV RT assay, 30 samples with
50 two controls (prepared by end user) were analyzed using a single ExaVir Load assay
51 kit. Basic instruments were included as capital costs, as these are necessary for a new
52 laboratory set-up. In the cost comparison analysis we did not consider costs associated
53
54
55
56
57
58
59
60

with the sample collection, storage and transportation as these are common to both tests.

Statistical Analysis

All statistical analyses were performed after the HIV RT and HIV-1 RNA level values were \log_{10} transformed. For analysis, the lower limit of detection of HIV RT assay (≤ 200 copies/mL) was considered; samples showing < 200 copies/mL by any of the assays were assigned a value of 199 copies/mL. With Exavir Load v3 we achieved a varying upper detection limit ranging from $> 360,000$ to $> 770,000$ in different runs. Thus samples with a viral load of $> 360,000$ (the lowest range of upper detection limit obtained for ExaVir Load v3) by any of the assays were assigned a viral load of 360,000 copies/mL. The diagnostic agreement between HIV RT assay and HIV-1 RNA assay at different viral load cut-offs was determined from the kappa statistic. Pearson's correlation coefficient (r) was calculated to study the correlation between \log_{10} HIV RT activity (copies/ml equivalents) and \log_{10} HIV RNA (copies/ml). However as this coefficient does not take in account the possibility that one measure may differ consistently from the other, we further assessed the level of agreement using pair-wise Bland-Altman plots. This plot compares the measures between the two tests by plotting the difference in the two VL measures against the average of the two measures.

Results

Sample characteristics

Plasma viral load was obtained from 629 samples collected from 327 HIV-1 infected adult patients, of which 302 were paired (before ART and 4 Weeks after ART initiation). HIV-1C was the predominant subtype observed in 98.1% (313/319) of the patients. Six out of 319 genotyped patients (1.9%) showed presence of non-C subtype strains namely BC recombinant (1), BD recombinant (1), A1C recombinant (2) and HIV-1A1 (2). Eleven patients (3.4%) showed presence of single primary drug resistant

mutations, with six samples harboring NRTI associated drug resistant mutations (DRMs) and five samples with NNRTI-associated mutations. (Table 1).

TABLE 1. Comparison of HIV-1 plasma VL levels measured by the HIV RT and HIV-1 RNA assays by antiretroviral treatment (ART) status, HIV-1 subtypes and RT-drug resistant mutations

Sample Type	Number of Samples	Mean viral load \pm SD in \log_{10} copies/mL		Mean \log_{10} viral load difference \pm SD in \log_{10} copies/mL
		ExaVir Load v3	Abbott m2000rt	
All samples	629	3.98 \pm 1.3	4.19 \pm 1.3	0.22 \pm 0.3
ART Status				
Naïve (baseline at WK00)	327	5.07 \pm 0.6	5.33 \pm 0.5	0.25 \pm 0.3
Experienced (WK04)	302	2.79 \pm 0.5	2.97 \pm 0.6	0.19 \pm 0.4
Subtype at WK00 (n=319)*				
C	313	5.08 \pm 0.6	5.33 \pm 0.4	0.25 \pm 0.3
Non-C	6	5.05 \pm 0.5	5.3 \pm 0.4	0.25 \pm 0.3
DRMs at WK00 (n=319)*				
Wild type (No DRM)	308	5.07 \pm 0.6	5.32 \pm 0.5	0.25 \pm 0.3
NRTI mutations	6	5.41 \pm 0.3	5.55 \pm 0.01	0.15 \pm 0.3
NNRTI mutations	5	5.26 \pm 0.2	5.62 \pm 0.2	0.36 \pm 0.2

*Genotyping performed only in baseline samples

Comparison between HIV RT activity and HIV-1 RNA load assay

There were 54 samples (8.5%) that were quantifiable by HIV-1 RNA assay but were below the detection limit of the HIV RT assay (Table 2). At a lower limit of quantification of 200 copies/mL, 90.7% of the samples showed quantifiable virus by HIV RT assay. The percentage of the samples with quantifiable viral load by HIV RT assay increased with higher viral load cut-offs by the HIV-1 RNA assay as shown in Table 2. Over all there was acceptable agreement observed between HIV RT and HIV-1 RNA assay, with excellent agreement observed at higher values of plasma viral load $\geq 3.0 \log_{10}$ copies/mL (Kappa = 0.76). Of all the samples, 81.7% (514/629) had viral

load values by HIV RT assay which, differed by $< 0.5 \log_{10}$ units from the HIV-1 RNA values; while 99.2% (624/629) of the samples differed by $< 1.0 \log_{10}$ units.

TABLE 2. Agreement between HIV RT assay and HIV-1 RNA assay at different plasma viral load levels.

PVL by HIV-1 RNA In copies/mL (\log_{10} copies/mL)	Agreement	Kappa Value	No. of samples detected by Abbott m2000rt	Percentage of Samples detected by ExaVir Load v3
≥ 200 (2.3)	89.1	0.46	580	90.7
≥ 400 (2.6)	88.1	0.57	550	93.5
≥ 1000 (3.0)	89.7	0.76	458	97.6
≥ 5000 (3.7)	94.4	0.89	344	99.7
$\geq 10,000$ (4.0)	96.8	0.94	324	100

A strong positive correlation was observed between the plasma viral load values by HIV RT and HIV-1 RNA assay ($r = 0.96$) in all the samples. A good correlation was noted in ART-naïve samples ($r = 0.84$) as well as in samples at Week 04 of ART ($r = 0.77$) (Fig. 1).

Bland-Altman plots for all the samples showed good levels of agreement with a mean difference (bias) of $0.22 \log_{10}$ copies/mL, with acceptable limits of agreement (-0.45 and $+0.89 \log_{10}$ copies/mL). A good level of agreement was also observed separately at baseline [mean difference bias of 0.25 ; range of acceptable limit of agreement: -0.39 and $+0.89 \log_{10}$ copies/mL] and at WK04 [mean difference bias of 0.19 ; range of acceptable limit of agreement: -0.52 and $+0.89 \log_{10}$ copies/mL]. (Fig. 2)

Influence of current anti-retroviral therapy and drug resistant mutations on RT-enzyme activity

Table 1 shows that the mean \log_{10} difference between HIV RT and HIV-1 RNA assay both before and after initiation of ART were not significantly different ($< 0.25 \log_{10}$ Copies/mL) and well within the clinically accepted limit of $0.5 \log_{10}$ copies/mL. Thus the performance of HIV RT assay is not affected by the presence of NNRTI

(nevirapine/efavirenz) based ART regimen. Also presence of either NRTI associated DRM's (n=6; M41L: 1, D67N: 1, T69D: 1, M184I: 1 and T215S: 2) and NNRTI associated DRM's (n=5; Y181C: 1, K101E: 1 and K103N: 2) showed an acceptable change ($<0.4 \log_{10}$ Copies/mL) in mean \log_{10} difference from the corresponding value among wild types. Although the samples with mutations are small, it indicates that the presence of NRTI and NNRTI DRM's did not negatively impact the test performance.

Cost comparison of the assays

The laboratory cost of viral load monitoring of HIV-infected patients analyzed in our cohort by both Abbott m2000rt (HIV-1 RNA) and ExaVir Load v3 (HIV RT) is shown in Table 2. The per test cost of the plasma viral load measure by Abbott m2000rt and ExaVir Load v3 was \$36.4 and \$17.3 respectively. Thus, by using the ExaVir Load v3, \$19.1 per test can be saved. In a laboratory with a pre-existing basic set up for ELISA based assays, the ExaVir Load v3 can be performed at \$16.8, saving \$19.6 per test. Most of the expense saved by using ExaVir Load v3 were due to (a) lower capital costs (instruments \$37750 against \$2000) (b) the lower cost of the assay reagents (\$15/test against \$31/test) (Table 3).

TABLE 3. Cost comparison between HIV RT assay and HIV-1 RNA assay for a laboratory doing 6000 tests/ year

Parameters	Abbott m2000rt Cost (\$)	ExaVir Load v3 Cost (\$)
Capital Instruments	37750	2000
Annual Maintenance Cost for 5 years	4458	923/0*
Operator supplied Instruments	840	6830/0*
Reagents for 5 years	465000	225000
Consumables for 5 years	23076.9	9230.8
Salary costs @ \$250/month for 5 years	15000	15000
Total expenditure for 5 years	5,46,124.9	2,58,983.8/2,51,230.8*
Cost/test (\$)	36.41	17.27/16.75*

*Cost for laboratories already furnished with a set up for ELISA based assays.

Discussion

A good correlation between the HIV RT and the HIV-1 RNA assays was observed in the current HIV-1C predominant setting in India. The agreement between the tests was not significantly affected by the NRTI/NNRTI based anti-retroviral regimen used. Earlier studies performed on panels of different subtypes and recombinants have suggested that the HIV RT assay detects all HIV- 1 and HIV- 2 subtypes with similar efficiency.[14 15 30] This assay, ExaVir Load version 3, can therefore be an attractive option for viral load monitoring in Indian settings.

The current study compared the ExaVir Load assay v3 with Abbott m2000rt HIV-1 RNA assay and observed an excellent correlation ($r=0.96$). An earlier study from London comparing the same tests observed a similar correlation ($r=0.94$).[14] Strong correlations between ExaVir Load v3 and Roche HIV-1 RNA-based assays have also been observed by two other studies, by Greengrass *et al.* from Australia (Roche Cobas Amplicor; $r=0.85$) and Huang *et al.* from China (Roche Cobas TaqMan 48; $r=0.95$).[16 18] Neither of these studies was performed in HIV-1C dominated settings. The HIV RT assay showed a good agreement with the HIV-1 RNA assay at the clinically important viral load threshold of 1000 copies/mL, which is used by the World Health Organization (WHO) to define viral-failure to first line therapy and is also most often used as the cut-off for drug resistance genotyping.[31] The performance of Exavir Load below 1000 copies/mL is moderate.

In general, we observed an under estimation of viral load of 0.22 \log_{10} RNA copies by the HIV RT assay, which is similar to what have been observed in other studies.[14, 16, [32] These two surrogate assays use very different methods for quantifying the plasma viral load. The HIV-1 RNA assays quantify the amount of viral RNA irrespective of RNA functionality, while the HIV RT assay quantifies the amount of active RT enzyme. The calibration constant used to translate RT activity into RNA copies was estimated from a study of an Australian cohort [18] and is not completely accurate for all combinations of HIV RNA assays and cohorts with varying subtype compositions. The variation observed is, however, well within the acceptable limit of $<0.5 \log_{10}$ copies.

NNRTI drugs bind to the RT enzyme, inhibit its activity and prevent viral replication. Several articles have discussed the possibility that enzymatically inactive RT-drug

1
2
3 complexes could result in under quantification of RT in relation to RNA.[29, 30, [33]
4 These studies were however, cross-sectional and never found any evidence for reduced
5 RT activity during NNRTI therapy. In contrast to previous cohorts, the longitudinal
6 sampling in our study provides optimal material for evaluation of the effects of NNRTI
7 based drug regimens. When comparing HIV viral load data from the same patient
8 cohort before and after onset of ART, we found a mean \log_{10} difference between
9 ExaVir Load v3 and Abbott m2000rt of 0.25 for naïve patients and 0.19 for
10 experienced patients (Table 1). The difference between the tests did thus not increase
11 after onset of therapy. This supports evidence that the current NNRTI containing
12 therapy does not adversely influence the recovery of RT enzyme activity.
13
14
15
16
17
18
19

20
21 On a small number of samples, we assessed if the presence of drug resistant mutations
22 decreased the RT-fitness so as to influence the performance of HIV RT assay. We had
23 6 samples with single NRTI mutations and 5 samples with single NNRTI mutations
24 and observed no evidence that their presence caused any significant difference in the
25 association between RT-enzyme activity and HIV-1 RNA load. Despite the small
26 sample number, our results support evidence from previous studies by Napravnik *et al.*
27 and Van Rooijen *et al.* indicating that the presence of NRTI or NNRTI mutations do
28 not affect the relationship between RT-enzyme activity and HIV-1 RNA load. [34 35]
29
30
31
32
33

34
35 To our knowledge the current study is the most thoroughly evaluated study of ExaVir
36 Load v3 from India to date. Thus far, there have been three comparative studies from
37 India that have been reported from the states of Andhra Pradesh (Anantpur),[36] Tamil
38 Nadu (Chennai),[7] and New Delhi.[32] Iqbal *et al.* from Chennai cross-sectionally
39 evaluated ExaVir Load assay version 1 and Roche Amplicor Monitor assay. They
40 found a good agreement between the two tests and a significant inverse correlation
41 between ExaVir Load and CD4+ T-cell count.[7] Alvarez-Uria *et al.* from Anantpur
42 compared the accuracy of ExaVir version 3 with Roche Cobas TaqMan HIV-1 test and
43 Roche Amplicor HIV-1 DNA assay for early infant diagnosis. ExaVir performed well
44 showing 100 % sensitivity and 99 % specificity, but no quantitative correlations were
45 evaluated.[36] A more recent study by Kokkayil *et al.* compared ExaVir Load v3 with
46 Roche Cobas TaqMan among 75 ART naïve patients and reported no statistically
47 significant difference between the two assays.[32]
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 There are a few drawbacks of the HIV RT assay. The long turnaround time of 48 hours
4 makes it appear labor intensive though the actual hands-on time is approximately 5
5 hours. The prolonged incubation time is critical to achieve assay sensitivity. For
6 standard performance, the assay requires 1 mL of plasma, which is high in comparison
7 to the requirement for HIV-1 RNA assays, thus limiting its possible usefulness in
8 pediatric populations. However a recent study by Greengrass *et al.* observed that
9 sample volumes down to 0.25 ml with VL>800 copies/mL can be utilized for pediatric
10 monitoring.[19] The ExaVir Load assay does not provide a standard positive and
11 negative control, thus requiring the lab to prepare its own controls, which may
12 compromise the quality assurance of the assay. Additionally, we noted that the quality
13 of the water used for washing is important as impurities and bacterial contaminants
14 present in water may contain polymerases which can create background noise and
15 increase the level of the lower detection limit.
16
17

18
19 In spite of these caveats, the HIV RT assay has advantages over the HIV-1 RNA
20 assays in resource-limited settings because it is an ELISA based assay and can be
21 performed in any routine lab at a lower cost. The ExaVir Load assay requires a cheaper
22 and maintenance free startup kit as compared to real time assays. We observed that
23 performing the HIV RT assay routinely in our center would save us \$19.6 per sample
24 as compared to a HIV-1 RNA assay. A more basic laboratory, which requires installing
25 basic ELISA equipment, would save \$19.1 per sample (Table 3).
26
27

28
29 The use of CD4 cell count as a prognostic marker has been debated, it is argued that
30 this count may not reflect the actual viral load status of the patient.[37] The cost
31 associated with viral load monitoring using HIV-1 RNA assays, despite being lower
32 than PCR assays, is a major limiting factor for its implementation. Currently in India,
33 viral load testing has been phased in to support patients failing first line ART. In
34 the year 2012, about 4157 viral load tests were performed under National AIDS Control
35 Organisation (NACO).[38] Considering \$19.6 could have been saved per sample by
36 performing HIV RT assay, the cost saving for these 4157 viral load tests could have
37 amounted to \$ 81,477 if a HIV RT assay had been used.
38
39

40
41 NACO is now considering taking up the monitoring approach recommended by WHO
42 to diagnose and confirm ART failure. Considering that there currently are 604,987
43 HIV-1 infected individuals receiving first line of ART at 380 centers spread across the
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 country the cost reduction of utilizing HIV RT compared to HIV RNA plasma load can
4 be substantial.[39]
5
6

7 Scaling up ART requires the critical support of HIV-1 viral load monitoring. Evidence
8 from the comparative performance of the HIV RT assay with HIV-1 RNA assays from
9 ours and other studies from India, indicate that the ExaVir Load assay could serve as
10 an affordable alternative to monitor patients on ART.
11
12
13

14 15 16 17 18 19 20 **Acknowledgments** 21

22 The authors would like to thank the HIVIND study team for their outstanding efforts in
23 recruiting and following the study participants and collection of samples. Authors
24 would also like to thank Pravat Nalini Sahoo and Shwetha D Rao, St. John's Research
25 Institute to perform laboratory experiments pertaining to HIV-1 drug resistance and
26 HIV-1 RNA load. We are very much thankful to Staffan Sjö Dahl, Cavid AB for his
27 technical help and support with the ExaVir Load v3 assay. Ujjwal Neogi acknowledges
28 the support received from Karolinska Institutet Research Foundation Grants
29 (2014fobi41250). We also acknowledge the staff at the ART Centre, St. John's
30 Medical College Hospital and KR Hospital, Mysore for their excellent teamwork and
31 patient care and NACO and Karnataka State AIDS Prevention Society (KSAPS) for
32 their support. Most importantly, we are ever thankful to the patients for their
33 participation in the study.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Authors Contribution

Conceived the Study: UN ADC CK PA AS. Designed the experiments: SG UN HS ADC CK AS. Performed the experiments: SG RPC. External lab monitoring and interim quality assessment: PA. Analyzed the data: SG UN ADC CK AS. Contributed reagents/materials/analysis tools: CK AS. Contributed to the writing of the manuscript: SG RP UN HS PA ADC CK AS.

Competing interests

Clas Källander is an employee of Cavid AB, Uppsala, Sweden. All the other authors have declared that no competing interests exist.

Funding

The study was financially supported by a grant under the European Union Framework Program 7 (project no: 222946). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data sharing statement

All relevant data are included within the paper. No additional data available.

References

1. Neogi U, Heylen E, Shet A, et al. Long-term efficacy of first line antiretroviral therapy in Indian HIV-1 infected patients: a longitudinal cohort study. *PloS one* 2013;8(1):e55421 doi: 10.1371/journal.pone.0055421.
2. Antiretroviral Therapy Cohort C. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. *Lancet* 2008;372(9635):293-9 doi: 10.1016/S0140-6736(08)61113-7.
3. Bryant L, Smith N, Keiser P. A Model for Reduced HIV-1 Viral Load Monitoring in Resource-Limited Settings. *Journal of the International Association of Providers of AIDS Care* 2013;12(1):67-71 doi: 10.1177/1545109712442007.
4. Crowe S, Turnbull S, Oelrichs R, Dunne A. Monitoring of human immunodeficiency virus infection in resource-constrained countries. *Clin Infect Dis* 2003;37(Suppl 1):S25-35 doi: 10.1086/375369.
5. Rawizza HE, Chaplin B, Meloni ST, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. *Clin Infect Dis* 2011;53(12):1283-90 doi: 10.1093/cid/cir729.
6. Wilson D, Keiluhu AK, Kogrum S, et al. HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2009;103(6):601-6 doi: 10.1016/j.trstmh.2008.11.007.
7. Iqbal HS, Balakrishnan P, Cecelia AJ, et al. Use of an HIV-1 reverse-transcriptase enzyme-activity assay to measure HIV-1 viral load as a potential alternative to nucleic acid-based assay for monitoring antiretroviral therapy in resource-limited settings. *Journal of medical microbiology* 2007;56(Pt 12):1611-4 doi: 10.1099/jmm.0.47456-0.
8. Stewart P, Cachafeiro A, Napravnik S, et al. Performance characteristics of the Cavidix ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay. *J Clin Virol* 2010;49(3):198-204 doi: 10.1016/j.jcv.2010.07.022.

- 1
2
3 9. Stevens WS, Scott LE, Crowe SM. Quantifying HIV for monitoring antiretroviral
4 therapy in resource-poor settings. *The Journal of infectious diseases* 2010;201 Suppl
5 1:S16-26 doi: 10.1086/650392.
6
7
- 8
9 10. Sivapalasingam S, Wangechi B, Marshed F, et al. Monitoring virologic responses
10 to antiretroviral therapy in HIV-infected adults in Kenya: evaluation of a low-cost viral
11 load assay. *PloS one* 2009;4(8):e6828 doi: 10.1371/journal.pone.0006828.
12
13
- 14 11. Seyoum E, Wolday D, Girma M, et al. Reverse transcriptase activity for
15 quantitation of HIV-1 subtype C in plasma: relation to RNA copy number and CD4 T-
16 cell count. *J Med Virol* 2006;78(2):161-8 doi: 10.1002/jmv.20523.
17
18
- 19 12. Malmsten A, Shao XW, Sjudahl S, et al. Improved HIV-1 viral load determination
20 based on reverse transcriptase activity recovered from human plasma. *J Med Virol*
21 2005;76(3):291-6 doi: 10.1002/jmv.20360.
22
23
- 24 13. Lombart JP, Vray M, Kafando A, et al. Plasma virion reverse transcriptase activity
25 and heat dissociation-boosted p24 assay for HIV load in Burkina Faso, West Africa.
26 *AIDS (London, England)* 2005;19(12):1273-7.
27
28
- 29 14. Labbett W, Garcia-Diaz A, Fox Z, et al. Comparative evaluation of the ExaVir
30 Load version 3 reverse transcriptase assay for measurement of human
31 immunodeficiency virus type 1 plasma load. *J Clin Microbiol* 2009;47(10):3266-70
32 doi: 10.1128/JCM.00715-09.
33
34
- 35 15. Jennings C, Fiscus SA, Crowe SM, et al. Comparison of two human
36 immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay.
37 *J Clin Microbiol* 2005;43(12):5950-6 doi: 10.1128/JCM.43.12.5950-5956.2005.
38
39
- 40 16. Huang D, Zhuang Y, Zhai S, et al. HIV reverse transcriptase activity assay: a
41 feasible surrogate for HIV viral load measurement in China. *Diagnostic microbiology*
42 and infectious disease 2010;68(3):208-13 doi: 10.1016/j.diagmicrobio.2010.06.007.
43
44
- 45 17. Greengrass VL, Turnbull SP, Hocking J, et al. Evaluation of a low cost reverse
46 transcriptase assay for plasma HIV-1 viral load monitoring. *Current HIV research*
47 2005;3(2):183-90.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 18. Greengrass VL, Plate MM, Steele PM, et al. Evaluation of the CaviDi ExaVir Load
4 assay (version 3) for plasma human immunodeficiency virus type 1 load monitoring. *J*
5 *Clin Microbiol* 2009;47(9):3011-3 doi: 10.1128/JCM.00805-09.
6
7
8
9 19. Greengrass V, Lohman B, Morris L, et al. Assessment of the low-cost CaviDi
10 ExaVir Load assay for monitoring HIV viral load in pediatric and adult patients.
11 *Journal of acquired immune deficiency syndromes (1999)* 2009;52(3):387-90 doi:
12 10.1097/QAI.0b013e3181b05f62.
13
14
15
16 20. Shao Y, Williamson C. The HIV-1 epidemic: low- to middle-income countries.
17 *Cold Spring Harbor perspectives in medicine* 2012;2(3):a007187 doi:
18 10.1101/cshperspect.a007187.
19
20
21
22 21. Mine M, Bedi K, Maruta T, et al. Quantitation of human immunodeficiency virus
23 type 1 viral load in plasma using reverse transcriptase activity assay at a district
24 hospital laboratory in Botswana: a decentralization pilot study. *Journal of virological*
25 *methods* 2009;159(1):93-7 doi: 10.1016/j.jviromet.2009.03.008.
26
27
28
29 22. Stevens G, Rekhviashvili N, Scott LE, Gonin R, Stevens W. Evaluation of two
30 commercially available, inexpensive alternative assays used for assessing viral load in
31 a cohort of human immunodeficiency virus type 1 subtype C-infected patients from
32 South Africa. *J Clin Microbiol* 2005;43(2):857-61 doi: 10.1128/JCM.43.2.857-
33 861.2005.
34
35
36
37 23. Shet A, Costa AD, Kumarasamy N, et al. Effect of mobile telephone reminders on
38 treatment outcome in HIV: evidence from a randomised controlled trial in India. *BMJ*
39 2014;347:g5978-g78 doi: 10.1136/bmj.g5978.
40
41
42
43 24. NACO, Department of AIDS Control, Ministry of Health and Family Welfare,
44 Annual Report 2012-13 available at
45 [http://www.nacoonline.org/upload/Publication/Annual_Report/Annual_report_2012-](http://www.nacoonline.org/upload/Publication/Annual_Report/Annual_report_2012-13_English.pdf)
46 [13_English.pdf](http://www.nacoonline.org/upload/Publication/Annual_Report/Annual_report_2012-13_English.pdf) accessed on 8 July 2013.
47
48
49
50 25. Neogi U, Prarthana BS, Gupta S, et al. Naturally occurring polymorphisms and
51 primary drug resistance profile among antiretroviral-naive individuals in Bangalore,
52 India. *AIDS research and human retroviruses* 2010;26(10):1097-101 doi:
53 10.1089/aid.2010.0092.
54
55
56
57
58
59
60

- 1
2
3 26. Gupta S, Neogi U, Srinivasa H, Banerjea AC, Shet A. HIV-1 co-receptor tropism
4 in India: increasing proportion of X4-tropism in subtype C strains over two decades.
5 Journal of acquired immune deficiency syndromes (1999) 2013 doi:
6 10.1097/qai.0000000000000046.
7
8
9
10 27. Neogi U, Bontell I, Shet A, et al. Molecular epidemiology of HIV-1 subtypes in
11 India: origin and evolutionary history of the predominant subtype C. PloS one
12 2012;7(6):e39819 doi: 10.1371/journal.pone.0039819.
13
14
15 28. Neogi U, Gupta S, Palchaudhuri R, et al. Limited evolution but increasing trends of
16 primary non-nucleoside reverse transcriptase inhibitor resistance mutations in therapy-
17 naive HIV-1-infected individuals in India. Antiviral therapy 2014 doi:
18 10.3851/imp2769.
19
20
21 29. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for
22 surveillance of transmitted HIV-1 drug-resistance: 2009 update. PloS one
23 2009;4(3):e4724 doi: 10.1371/journal.pone.0004724.
24
25
26 30. Steegen K, Luchters S, De Cabooter N, et al. Evaluation of two commercially
27 available alternatives for HIV-1 viral load testing in resource-limited settings. Journal
28 of virological methods 2007;146(1-2):178-87 doi: 10.1016/j.jviromet.2007.06.019.
29
30
31 31. World Health Organization. Consolidated guidelines on the use of antiretroviral
32 drugs for treating and preventing HIV infection. Recommendations for a public health
33 approach. Geneva, Switzerland. 2013.
34
35
36 32. Kokkayil P, Kurapati S, Negi N, Vajpayee M. Comparative evaluation of a reverse
37 transcriptase based assay for HIV-1 viral load quantitation in resource limited settings.
38 Journal of virological methods 2014;203:1-4 doi: 10.1016/j.jviromet.2014.02.021.
39
40
41 33. Malmsten A, Shao XW, Aperia K, et al. HIV-1 viral load determination based on
42 reverse transcriptase activity recovered from human plasma. J Med Virol
43 2003;71(3):347-59 doi: 10.1002/jmv.10492.
44
45
46 34. van Rooijen LB, Greengrass V, Morris LM, et al. Effect of reverse transcriptase
47 inhibitors and mutations on the low-cost Cavid reverse transcriptase viral load assay.
48 Journal of acquired immune deficiency syndromes (1999) 2009;52(4):527-9 doi:
49 10.1097/QAI.0b013e3181b9e726.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 35. Napravnik S, Cachafeiro A, Stewart P, Eron JJ, Jr., Fiscus SA. HIV-1 viral load
4 and phenotypic antiretroviral drug resistance assays based on reverse transcriptase
5 activity in comparison to amplification based HIV-1 RNA and genotypic assays.
6 Journal of clinical virology : the official publication of the Pan American Society for
7 Clinical Virology 2010;47(1):18-22 doi: 10.1016/j.jcv.2009.10.001.
8
9
10
11 36. Gerardo Alvarez-Uria JMA, Srinivasulu Reddy, Manoranjan Midde, Praveen K.
12 Naik, N. Raghuprakash Reddy Point of care testing of HIV in children younger than 18
13 months with three different HIV virological assays. Experience from a district hospital
14 in a resource-limited setting. Microbiology Research 2012;3(1):e14 doi:
15 10.4081/mr.2012.e14.
16
17 37. Sax PE. Editorial commentary: can we break the habit of routine CD4 monitoring
18 in HIV care? Clin Infect Dis 2013;56(9):1344-6 doi: 10.1093/cid/cit008.
19
20
21 38. Ataher Q, Portsmouth S, Napolitano LA, et al. The epidemiology and clinical
22 correlates of HIV-1 co-receptor tropism in non-subtype B infections from India,
23 Uganda and South Africa. J Int AIDS Soc 2012;15(1):2.
24
25 39. Vitoria M, Vella S, Ford N. Scaling up antiretroviral therapy in resource-limited
26 settings: adapting guidance to meet the challenges. Curr Opin HIV AIDS
27 2013;8(1):12-8 doi: 10.1097/COH.0b013e32835b8123.
28
29
30
31
32
33
34
35
36
37
38
39

40 **Figure Legends:**

41
42 **Figure 1:** Correlation between Abbott m2000rt and ExaVir Load v3 assay for A) all
43 629 samples showing $r = 0.96$ B) 327 baseline (WK00) samples showing $r =$
44 0.84 and C) 302 4-weeks post-ART (WK04) samples showing $r = 0.77$.
45
46
47

48 **Figure 2:** Bland-Altman plot with 95% CI of limits of agreement between HIV-1 viral
49 loads measured with Abbott Real-Time m2000rt assay and ExaVir Load v3 assay for
50 A) all 629 samples showing a mean bias of 0.22 with 95% limits of agreement ranging
51 from -0.45 to 0.89 B) 327 baseline (WK00) samples showing a mean bias of 0.25 with
52 95% limits of agreement ranging from -0.39 to 0.89 C) 302 4-weeks post-ART
53 (WK04) samples showing a mean bias of 0.19 with 95% limits of agreement ranging
54 from -0.52 to 0.89.
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1A




Figure 1B




Figure 1C




Figure 2A




Figure 2B





Figure 2C



BMJ Open

Can HIV reverse transcriptase activity assay be a low cost alternative for viral load monitoring in resource-limited settings?

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-008795.R1
Article Type:	Research
Date Submitted by the Author:	16-Nov-2015
Complete List of Authors:	Gupta, Soham; St. John's Medical College, Microbiology Palchaudhuri, Riya; St. John's Medical College, Microbiology Neogi, Ujjwal; Karolinska Institutet, Laboratory Medicine Srinivasa, Hiresave; St. John's Medical College, Microbiology Ashorn, Per; University of Tampere School of Medicine, International Health de Costa, Ayesha; Karolinska Institutet, Department of Public Health Sciences Källander, Clas; Cavid AB, Research and Development Shet, Anita; St John's Medical College Hospital, Pediatrics
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	HIV/AIDS, Infectious diseases
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Diagnostic microbiology < INFECTIOUS DISEASES, Molecular diagnostics < INFECTIOUS DISEASES, Infection control < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts

1
2
3 **Can HIV reverse transcriptase activity assay be a low cost alternative for viral**
4 **load monitoring in resource-limited settings?**
5

6 Soham Gupta^{1*}, Riya Palchadhuri¹, Ujjwal Neogi^{2*}, Hiresave Srinivasa¹, Per Ashorn³,
7 Ayesha De Costa⁴, Clas Källander⁵, Anita Shet⁶
8

9 ¹Division of Clinical Virology, Department of Microbiology, St. John's medical
10 College, Bangalore, India

11 ²Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska
12 Institutet, Stockholm, Sweden.

13 ³Department for International Health, University of Tampere School of Medicine,
14 Finland

15 ⁴Department of Public Health Sciences, Karolinska Institute, Stockholm, Sweden

16 ⁵Cavidi AB, Uppsala, Sweden

17 ⁶Department of Pediatrics, St John's Medical College Hospital, Bangalore, India
18
19
20
21
22
23
24

25 ***Corresponding Author:**

26 E-mail: soham.micro@gmail.com (SG); ujjwal.neogi@ki.se (UN)
27
28
29
30

31 **Running Title:** Low cost HIV viral load monitoring
32
33
34

35 **Word Count:** 3870
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Key Words: HIV-1 viral load monitoring; HIV reverse transcriptase activity assay;
Real time PCR; Resource-limited settings

Abstract

Objective: To evaluate the performance and cost of an HIV reverse transcriptase-enzyme activity (HIV-RT) assay in comparison to a HIV-1 RNA assay for routine viral load monitoring in resource limited settings.

Design: Cohort based longitudinal study.

Setting: Two antiretroviral therapy (ART) centers in Karnataka state, South India, providing treatment under the Indian AIDS control program

Participants: Cohort of 327 HIV-1 infected Indian adult patients initiating first-line ART.

Outcome measures: The performance and cost of an HIV-RT assay (ExaVir Load v3) in comparison to a gold standard HIV-1 RNA assay (Abbott m2000rt) in a cohort of 327 Indian patients before (WK00) and 4 weeks (WK04) after initiation of first-line therapy.

Results: Plasma viral load was determined by HIV-1 RNA assay and HIV-RT assay in 629 samples (302 paired samples and 25 single time-point samples at WK00) obtained from 327 patients. Overall, a strong correlation of $r=0.96$ was observed, with good correlation at WK00 ($r = 0.84$) and at WK04 ($r = 0.77$). Bland-Altman analysis of all samples showed a good level of agreement with a mean difference (bias) of 0.22 \log_{10} copies/mL. The performance of ExaVir Load v3 was not negatively affected by a nevirapine/efavirenz based anti-retroviral regimen. The per test cost of measuring plasma viral load by Abbott m2000rt and ExaVir Load v3 assay in a basic lab setting was \$36.4 and \$16.8 respectively.

Conclusions: The strong correlation between HIV-RT and HIV-1 RNA assay suggests that the HIV-RT assay can be an affordable alternative option for monitoring patients on anti-retroviral therapy in resource-limited settings.

Strengths and Limitations of this study:

- To our knowledge the current study is the most thoroughly evaluated study of ExaVir Load v3 (HIV-RT assay) from India to date.
- This study was performed in a large number of subjects in a longitudinal manner looking into the effects of the NNRTI based therapy and drug resistance mutations on the performance of the HIV RT-enzyme activity assay.
- Though the assay has been validated before in other non-C subtype settings, in the present study the HIV-RT assay was validated on a larger scale in a subtype C predominant setting and subtype C is the most predominant subtype globally, more so affecting the resource limited settings.
- This study was limited to patients hailing from Southern India and a performance evaluation and cost-effectiveness of the HIV-RT assay needs to be accessed on a national level.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

The principle aim of anti-retroviral therapy (ART) is durable suppression of replicating plasma virus to undetectable levels, thereby delaying disease progression and prolonging survival.[1 2] Expanding access to ART in resource-limited settings along with close monitoring is needed for successful treatment outcomes. In high income settings this is achieved by performing quantitative viral load monitoring every 3-6 months,[3] as viral load monitoring detects early treatment failure. However in resource-limited settings therapeutic outcome is evaluated based on either CD4 T cell count or on clinical findings,[4] neither of which accurately predicts viral suppression.[5] Early detection of viral-failure by monitoring viral load also provides the opportunity to intensify adherence counseling to improve adherence to ART potentially leading to re-suppression of viral load before the evolution of drug resistant virus can take place.[6]

The currently used viral load assays are based on the amplification of HIV-1 virion RNA, which is considered impractical for wide-scale use in resource-limited settings, as it requires infrastructure, facilities for molecular diagnostics, expensive equipment and skilled technicians which are often unavailable.[7] Simpler, less expensive viral load assays would be very useful in the resource-limited environments that are most impacted by this epidemic.

An alternative to measure the HIV-1 RNA is to measure the activity of the viral reverse transcriptase (RT) enzyme. ExaVir Load assay (Cavidi, AB, Sweden), a low-cost and technically less-demanding assay using an enzyme linked immune sorbent assay (ELISA)-based method to measure RT enzyme activity has shown promising results.[8-19] Although previous versions of the test have been evaluated against several polymerase chain reaction (PCR)-based HIV tests that measure viral RNA, there are few comparative studies between ExaVir Load version 3 (v3) and such molecular real time assays.[14 16 18] The most recent version 3 of the ExaVir Load assay has an enhanced sensitivity (lower detection limit 200 copies/mL) and reduced turnaround time compared to version 2.[14 18]

HIV-1 subtype C (HIV-1C) is the dominant strain in most low middle-income countries like India, South Africa and Ethiopia [20] and the need for a simple low cost viral load monitoring tool is a priority in these settings. Data available from countries

1
2
3 dominated by the HIV-1C epidemic are limited. Where available, evaluations have
4 been mainly performed with earlier version assays (ExaVir Load v1 and v2), which
5 had lower detection limits of 400 copies/mL.[7 11 21 22] Studies evaluating ExaVir
6 Load v3 have been mainly performed in non-C dominated countries.[14 16 18 19]
7
8

9
10 Thus, we aimed to evaluate the performance of the HIV RT-enzyme activity (HIV RT)
11 assay (ExaVir Load v3) in comparison to a “gold standard” HIV RNA load (Abbott
12 m2000rt real-time PCR) assay in a cohort of patients before and after initiation of first-
13 line ART in Indian settings. We also compared viral load measurements from both
14 assays in a subset of patients with drug resistant mutations at baseline. Further, we
15 studied the difference in costs of the two viral load assays in the context of our
16 laboratory setting from a provider perspective.
17
18
19
20
21
22
23
24

25 **Materials and Methods**

26 *Study participants and samples*

27
28
29
30 Between April 2010 and September 2011, EDTA plasma samples were collected from
31 HIV-1 infected adult patients attending Infectious Disease Clinic, St. John’s Medical
32 College and Hospital, Bangalore (main site) and ART center, Krishna Rajendra
33 Hospital, Mysore (peripheral site) enrolled in the HIVIND randomized controlled trial
34 (Trial registration: ISRCTN79261738).[23] All the patients included in the study
35 initiated ART with reverse transcriptase inhibitor (RTI) drugs, i.e. two nucleoside
36 reverse transcriptase inhibitors (NRTI), zidovudine (AZT) or stavudine (d4T) with
37 lamivudine (3TC) + one non-nucleoside reverse transcriptase inhibitors (NNRTI),
38 either Nevirapine (NVP) or Efavirenz (EFV) as per the standard national AIDS
39 program guidelines.[24]
40
41
42
43
44
45
46
47

48 Plasma samples were collected at two time points; (i) prior to ART initiation (not
49 longer than 3 months prior) and (ii) 4 weeks after ART initiation. The plasma samples
50 were separated within 6 hours of EDTA whole blood collection, aliquoted and stored at
51 -80°C in the main site. Plasma samples aliquoted in the peripheral site were stored at -
52 20°C and were transported to the main site on dry ice (every 2 weeks) and then stored
53 at -80°C prior to testing.
54
55
56
57
58
59
60

Ethical statement

Ethical approvals for the conduct of the trial were obtained from Institutional Ethical Review Board of St John's Medical College Hospital, Bangalore (IERB 1/369/08–92/2008) and Krishna Rajendra Hospital, Mysore (NO/PS/173/2010). All patients participating in the HIVIND study have given their written consent.

Plasma HIV-1 RNA assay

Plasma HIV-1 RNA load was measured in the patient cohort using Abbott Real Time PCR, m2000rt system with manual RNA extraction procedure on m2000sp sample preparation system as per the manufacturer's instructions. The assay was performed using an initial volume of 0.2 mL plasma, which provides limits of quantification between 150 copies/mL (lower limit of detection) to 10,000,000 copies/mL (upper limit of detection). In every run a negative control, a low positive control and a high positive control supplied in the Abbott Realtime HIV-1 control kit were included. This measure using Real Time PCR was considered as the gold standard. This protocol was validated by an external quality control program by the Quality Control for Molecular Diagnostics, Glasgow, Scotland (QCMD, <http://www.qcmd.gov>) on 2010 panel (Consisting of four HIV-1B samples, two HIV-1C samples, one HIV-1A/G sample and one HIV-1 negative sample) and obtained highly satisfactory score.

Plasma HIV RT enzyme activity assay

The viral RT enzyme activity was quantified using Cavid ExaVir Load v3 as per the instructions of the manufacturer [14]. In an ELISA based format, the RT activity of the RT enzyme recovered from 1mL of patient plasma was determined and compared to a standard curve based on known amounts of a HIV 1 recombinant RT constructed from the BH10 isolate. The RT activity in the sample was expressed as femtogram HIV-1 RT activity/mL (fg/mL) plasma that was translated into RNA copies/mL equivalent by the ExaVir Load analyzer software. The lower detection limit of the assay was $\geq 1\text{fg/mL}$ i.e. $\geq 200\text{copies/mL}$. In every run a single positive control and a negative control were used to monitor the performance of the RT extraction process and to

1
2
3 access between run variations. The positive control was prepared by pooling the EDTA
4 plasma from a high HIV-1 viral load sample and HIV-1 negative plasma; 1.2mL was
5 aliquoted and stored in -80°C freezer. The laboratory personnel running the ExaVir
6 Load v3 assay were blind to the plasma HIV-1 RNA values.
7
8
9

10 11 12 ***HIV-1 subtyping and baseline drug resistance*** 13

14
15 Genotypic resistance testing (GRT) was performed on the baseline plasma samples.
16 Briefly, the reverse transcriptase (RT) region of the HIV-1 *pol* gene was amplified and
17 sequenced using the primers described by us previously.[25] HIV-1 subtyping was
18 determined based on the *pol* gene as well as the *env* gene (wherever sequence data was
19 available).[26-28] using the maximum likelihood (ML) phylogenetic tree based on
20 reference sequences downloaded from Los Alamos Database (www.hiv.lanl.gov).
21 Primary drug resistance analysis was evaluated using World Health Organization list
22 of mutations from 2009 (WHO_SDRM 2009).[29]
23
24
25
26
27
28
29
30
31

32 ***Comparative cost analysis*** 33

34 We did an analysis comparing the costs between the Abbott m2000rt and the ExaVir
35 Load v3 from a provider (laboratory service provider) perspective. We used costs from
36 our lab for this purpose. Costs considered included annuitized capital costs for the two
37 different instruments including operator-supplied instruments. These are instruments,
38 which are necessary in case of a new laboratory. In case of Abbott the operator-
39 supplied instruments included single-channel micropipettes, two dry baths and a
40 vortex. For the ExaVir Load v3, micropipettes (both single-channel and multi-
41 channel), an ELISA plate reader, an incubator, a rocker and a vortex.
42
43
44
45
46
47

48 Cost for start-up kits, human resource costs (including time for training), annual
49 maintenance, reagents and other consumables were also considered. . We assumed the
50 working life for the Abbott m2000rt and the ExaVir Load v3 to be five years, and a
51 discount rate of 5% was applied.
52
53
54
55
56
57
58
59
60

Assumptions:

Number of patients: There are at present, 1500 ART-experienced patients in our ART center. Assuming that viral load monitoring of these patients will require to be performed every six months, there will be 3000 samples a year.

Maintenance costs: In the case of the Abbott m2000rt the costs for servicing, maintenance of instrument and calibration of laser head. In the case of ExaVir Load, there are no formal annual maintenance cost, however costs for maintenance of the operator supplied equipment has been assumed to be 10% of the cost of purchase of these equipment.

Human resource skills and training requirements: From our experience, 1 month was required to train a technician on the Abbott m2000rt. One week was required for training on the ExaVir load v3. We also considered that the technician handling the Abbott m2000rt would require to be more senior and experienced (salary 300 USD per month) compared to the technician working with the ExaVir Load v3 (salary 200 USD per month).

Time for each method of testing: For the Abbot m2000rt, a batch of 24 reactions which comprise 21 samples and 3 controls will involve a total time of 8 hours (from the beginning of RNA extraction up until obtaining results), of which 5 hours involve the technician's time. For Exavir Load v3, assay is done in batches of 30 samples. Though the turnaround time is 48 hours, it involves 5 hours of actual hands-on time per batch. Costs for time of the technicians was calculated against the salaries mentioned above

In the cost comparison analysis we did not consider costs associated with the sample collection, storage and transportation as these are common to both tests.

Statistical Analysis

All statistical analyses were performed after the HIV RT and HIV-1 RNA level values were \log_{10} transformed. For analysis, the lower limit of detection of HIV RT assay (≤ 200 copies/mL) was considered; samples showing < 200 copies/mL by any of the assays were assigned a value of 199 copies/mL. With Exavir Load v3 we achieved a varying upper detection limit ranging from $> 360,000$ to $> 770,000$ in different runs.

1
2
3 Thus samples with a viral load of >360,000 (the lowest range of upper detection limit
4 obtained for ExaVir Load v3) by any of the assays were assigned a viral load of
5 360,000 copies/mL. The diagnostic agreement between HIV RT assay and HIV-1
6 RNA assay at different viral load cut-offs was determined from the kappa statistic.
7
8 Pearson's correlation coefficient (r) was calculated to study the correlation between
9
10 log₁₀ HIV RT activity (copies/ml equivalents) and log₁₀ HIV RNA (copies/ml).
11
12 However as this coefficient does not take in account the possibility that one measure
13 may differ consistently from the other, we further assessed the level of agreement
14 using pair-wise Bland-Altman plots. This plot compares the measures between the two
15 tests by plotting the difference in the two VL measures against the average of the two
16 measures.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 Results

38 *Sample characteristics*

39
40 Plasma viral load was obtained from 629 samples collected from 327 HIV-1 infected
41 adult patients, of which 302 were paired (before ART and 4 Weeks after ART
42 initiation). HIV-1C was the predominant subtype observed in 98.1% (313/319) of the
43 patients. Six out of 319 genotyped patients (1.9%) showed presence of non-C subtype
44 strains namely BC recombinant (1), BD recombinant (1), A1C recombinant (2) and
45 HIV-1A1 (2). Eleven patients (3.4%) showed presence of single primary drug resistant
46 mutations, with six samples harboring NRTI associated drug resistant mutations
47 (DRMs) and five samples with NNRTI-associated mutations. (Table 1).
48
49
50
51
52
53
54
55
56
57
58
59
60

TABLE 1. Comparison of HIV-1 plasma VL levels measured by the HIV RT and HIV-1 RNA assays by antiretroviral treatment (ART) status, HIV-1 subtypes and RT-drug resistant mutations

Sample Type	Number of Samples	Mean viral load \pm SD in \log_{10} copies/mL		Mean \log_{10} viral load difference \pm SD in \log_{10} copies/mL
		ExaVir Load v3	Abbott m2000rt	
All samples	629	3.98 \pm 1.3	4.19 \pm 1.3	0.22 \pm 0.3
ART Status				
Naïve (baseline at WK00)	327	5.07 \pm 0.6	5.33 \pm 0.5	0.25 \pm 0.3
Experienced (WK04)	302	2.79 \pm 0.5	2.97 \pm 0.6	0.19 \pm 0.4
Subtype at WK00 (n=319)*				
C	313	5.08 \pm 0.6	5.33 \pm 0.4	0.25 \pm 0.3
Non-C	6	5.05 \pm 0.5	5.3 \pm 0.4	0.25 \pm 0.3
DRMs at WK00 (n=319)*				
Wild type (No DRM)	308	5.07 \pm 0.6	5.32 \pm 0.5	0.25 \pm 0.3
NRTI mutations	6	5.41 \pm 0.3	5.55 \pm 0.01	0.15 \pm 0.3
NNRTI mutations	5	5.26 \pm 0.2	5.62 \pm 0.2	0.36 \pm 0.2

*Genotyping performed only in baseline samples

Comparison between HIV RT activity and HIV-1 RNA load assay

There were 54 samples (8.5%) that were quantifiable by HIV-1 RNA assay but were below the detection limit of the HIV RT assay (Table 2). At a lower limit of quantification of 200 copies/mL, 90.7% of the samples showed quantifiable virus by HIV RT assay. The percentage of the samples with quantifiable viral load by HIV RT assay increased with higher viral load cut-offs by the HIV-1 RNA assay as shown in Table 2. Over all there was acceptable agreement observed between HIV RT and HIV-1 RNA assay, with excellent agreement observed at higher values of plasma viral load $\geq 3.0 \log_{10}$ copies/mL (Kappa = 0.76). Of all the samples, 81.7% (514/629) had viral load values by HIV RT assay which, differed by $< 0.5 \log_{10}$ units from the HIV-1 RNA values; while 99.2% (624/629) of the samples differed by $< 1.0 \log_{10}$ units.

TABLE 2. Agreement between HIV RT assay and HIV-1 RNA assay at different plasma viral load levels.

PVL by HIV-1 RNA In copies/mL (log ₁₀ copies/mL)	Agreement	Kappa Value	No. of samples detected by Abbott m2000rt	Percentage of Samples detected by ExaVir Load v3
≥ 200 (2.3)	89.1	0.46	580	90.7
≥ 400 (2.6)	88.1	0.57	550	93.5
≥ 1000 (3.0)	89.7	0.76	458	97.6
≥ 5000 (3.7)	94.4	0.89	344	99.7
≥ 10,000 (4.0)	96.8	0.94	324	100

A strong positive correlation was observed between the plasma viral load values by HIV RT and HIV-1 RNA assay ($r = 0.96$) in all the samples. A good correlation was noted in ART-naïve samples ($r = 0.84$) as well as in samples at Week 04 of ART ($r = 0.77$) (Fig. 1).

Bland-Altman plots for all the samples showed good levels of agreement with a mean difference (bias) of 0.22 log₁₀copies/mL, with acceptable limits of agreement (-0.45 and +0.89 log₁₀copies/mL). A good level of agreement was also observed separately at baseline [mean difference bias of 0.25; range of acceptable limit of agreement: -0.39 and +0.89 log₁₀copies/mL] and at WK04 [mean difference bias of 0.19; range of acceptable limit of agreement: -0.52 and +0.89 log₁₀copies/mL]. (Fig. 2)

Influence of current anti-retroviral therapy and drug resistant mutations on RT-enzyme activity

Table 1 shows that the mean log₁₀ difference between HIV RT and HIV-1 RNA assay both before and after initiation of ART were not significantly different (<0.25 log₁₀ Copies/mL) and well within the clinically accepted limit of 0.5 log₁₀copies/mL. Thus the performance of HIV RT assay is not affected by the presence of NNRTI (nevirapine/efavirenz) based ART regimen. Also presence of either NRTI associated DRM's (n=6; M41L: 1, D67N: 1, T69D: 1, M184I: 1 and T215S: 2) and NNRTI associated DRM's (n=5; Y181C: 1, K101E: 1 and K103N: 2) showed an acceptable change (<0.4 log₁₀ Copies/mL) in mean log₁₀ difference from the corresponding value

among wild types. Although the samples with mutations are small, it indicates that the presence of NRTI and NNRTI DRM's did not negatively impact the test performance.

Cost comparison of the assays

The laboratory cost of viral load monitoring of HIV-infected patients analyzed in our cohort by both Abbott m2000rt (HIV-1 RNA) and ExaVir Load v3 (HIV RT) is shown in Table 2. The per test cost of the plasma viral load measure by Abbott m2000rt and ExaVir Load v3 was \$36.4 and \$16.8 respectively. Thus, by using the ExaVir Load v3, \$19.6 per test can be saved. In a laboratory with a pre-existing basic set up for ELISA based assays, the ExaVir Load v3 can be performed at \$16.1, saving \$20.2 per test. Most of the expense saved by using ExaVir Load v3 were due to (a) lower capital costs (instruments \$37750 against \$2000) (b) the lower cost of the assay reagents (\$15/test against \$31/test) (Table 3).

TABLE 3. Cost comparison between HIV RT assay and HIV-1 RNA assay for a laboratory doing 3000 tests/ year

Cost items (\$)	Abbott m2000rt Cost (\$)	ExaVir Load v3 Cost (\$)
Annuitized costs of Capital Instruments	8719	462
Annuitized cost of Operator supplied Instruments[#]	293	1540
Annual Maintenance Cost	1126	666
Costs of kits per year	93000	45000
Consumables per year	4616	1846
Training time for lab staff to run the test	300	50
Salary costs (3000 tests per year)	1200	1000
Total (\$)	109634	50534
Cost/test (\$)	36.4	16.8

1 USD= 60 INR.

Discussion

A good correlation between the HIV RT and the HIV-1 RNA assays was observed in the current HIV-1C predominant setting in India. The agreement between the tests was not significantly affected by the NRTI/NNRTI based anti-retroviral regimen used. Earlier studies performed on panels of different subtypes and recombinants have suggested that the HIV RT assay detects all HIV-1 and HIV-2 subtypes with similar efficiency.[14 15 30] This assay, ExaVir Load version 3, can therefore be an attractive option for viral load monitoring in Indian settings.

The current study compared the ExaVir Load assay v3 with Abbott m2000rt HIV-1 RNA assay and observed an excellent correlation ($r=0.96$). An earlier study from London comparing the same tests observed a similar correlation ($r=0.94$).[14] Strong correlations between ExaVir Load v3 and Roche HIV-1 RNA-based assays have also been observed by two other studies, by Greengrass *et al.* from Australia (Roche Cobas Amplicor; $r=0.85$) and Huang *et al.* from China (Roche Cobas TaqMan 48; $r=0.95$).[16 18] Neither of these studies was performed in HIV-1C dominated settings. The HIV RT assay showed a good agreement with the HIV-1 RNA assay at the clinically important viral load threshold of 1000 copies/mL, which is used by the World Health Organization (WHO) to define viral-failure to first line therapy and is also most often used as the cut-off for drug resistance genotyping.[31] The performance of ExaVir Load below 1000 copies/mL is moderate.

In general, we observed an under estimation of viral load of 0.22 \log_{10} RNA copies by the HIV RT assay, which is similar to what have been observed in other studies.[14, 16, [32] These two surrogate assays use very different methods for quantifying the plasma viral load. The HIV-1 RNA assays quantify the amount of viral RNA irrespective of RNA functionality, while the HIV RT assay quantifies the amount of active RT enzyme. The calibration constant used to translate RT activity into RNA copies was estimated from a study of an Australian cohort [18] and is not completely accurate for all combinations of HIV RNA assays and cohorts with varying subtype compositions. The variation observed is, however, well within the acceptable limit of $<0.5 \log_{10}$ copies.

NNRTI drugs bind to the RT enzyme, inhibit its activity and prevent viral replication. Several articles have discussed the possibility that enzymatically inactive RT-drug

1
2
3 complexes could result in under quantification of RT in relation to RNA.[29, 30, [33]
4 These studies were however, cross-sectional and never found any evidence for reduced
5 RT activity during NNRTI therapy. In contrast to previous cohorts, the longitudinal
6 sampling in our study provides optimal material for evaluation of the effects of NNRTI
7 based drug regimens. When comparing HIV viral load data from the same patient
8 cohort before and after onset of ART, we found a mean \log_{10} difference between
9 ExaVir Load v3 and Abbott m2000rt of 0.25 for naïve patients and 0.19 for
10 experienced patients (Table 1). The difference between the tests did thus not increase
11 after onset of therapy. This supports evidence that the current NNRTI containing
12 therapy does not adversely influence the recovery of RT enzyme activity.
13
14
15
16
17
18
19

20
21 On a small number of samples, we assessed if the presence of drug resistant mutations
22 decreased the RT-fitness so as to influence the performance of HIV RT assay. We had
23 6 samples with single NRTI mutations and 5 samples with single NNRTI mutations
24 and observed no evidence that their presence caused any significant difference in the
25 association between RT-enzyme activity and HIV-1 RNA load. These results were not
26 unexpected and support evidence from previous studies by Napravnik *et al.* and Van
27 Rooijen *et al.* indicating that the presence of NRTI or NNRTI mutations do not affect
28 the relationship between RT-enzyme activity and HIV-1 RNA load. [34 35] Resistance
29 to NRTIs is mediated by a primitive DNA editing function that is introduced into the
30 HIV RT by certain mutations. An energy dependent base excision reaction removes the
31 last base in the growing DNA chain. This requires an energy donator, usually ATP or
32 GTP, and might decrease RT reaction velocity. This happens readily *in vivo*, but the
33 reaction conditions in the current RT assay do not support this reaction. [36]
34
35
36
37
38
39
40
41
42
43
44

45
46 To our knowledge the current study is the most thoroughly evaluated study of ExaVir
47 Load v3 from India to date. Thus far, there have been three comparative studies from
48 India that have been reported from the states of Andhra Pradesh (Anantpur),[37] Tamil
49 Nadu (Chennai),[7] and New Delhi.[32] Iqbal *et al.* from Chennai cross-sectionally
50 evaluated ExaVir Load assay version 1 and Roche Amplicor Monitor assay. They
51 found a good agreement between the two tests and a significant inverse correlation
52 between ExaVir Load and CD4+ T-cell count.[7] Alvarez-Uria *et al.* from Anantpur
53 compared the accuracy of ExaVir version 3 with Roche Cobas TaqMan HIV-1 test and
54
55
56
57
58
59
60

1
2
3 Roche Amplicor HIV-1 DNA assay for early infant diagnosis. ExaVir performed well
4 showing 100 % sensitivity and 99 % specificity, but no quantitative correlations were
5 evaluated.[37] A more recent study by Kokkayil *et al.* compared ExaVir Load v3 with
6 Roche Cobas TaqMan among 75 ART naïve patients and reported no statistically
7 significant difference between the two assays.[32]
8
9

10
11
12 There are a few drawbacks of the HIV RT assay. The long turnaround time of 48 hours
13 makes it appear labor intensive though the actual hands-on time is approximately 5
14 hours. The prolonged incubation time is critical to achieve assay sensitivity. For
15 standard performance, the assay requires 1 mL of plasma, which is high in comparison
16 to the requirement for HIV-1 RNA assays, thus limiting its possible usefulness in
17 pediatric populations. However a recent study by Greengrass *et al.* observed that
18 sample volumes down to 0.25 ml with VL>800 copies/mL can be utilized for pediatric
19 monitoring.[19] The ExaVir Load assay does not provide a standard positive and
20 negative control, thus requiring the lab to prepare its own controls, which may
21 compromise the quality assurance of the assay. Additionally, we noted that the quality
22 of the water used for washing is important as impurities and bacterial contaminants
23 present in water may contain polymerases which can create background noise and
24 increase the level of the lower detection limit.
25
26
27
28
29
30
31
32
33

34
35 In spite of these caveats, the HIV RT assay has advantages over the HIV-1 RNA
36 assays in resource-limited settings because it is an ELISA based assay and can be
37 performed in any routine lab at a lower cost. The ExaVir Load assay requires a cheaper
38 and maintenance free startup kit as compared to real time assays. We observed that
39 performing the HIV RT assay routinely in our center would save us \$20.2 per sample
40 as compared to a HIV-1 RNA assay. A more basic laboratory, which requires installing
41 basic ELISA equipment, would save \$19.6 per sample (Table 3).
42
43
44
45
46

47
48 The use of CD4 cell count as a prognostic marker has been debated, it is argued that
49 this count may not reflect the actual viral load status of the patient.[38] The cost
50 associated with viral load monitoring using HIV-1 RNA assays, despite being lower
51 than PCR assays, is a major limiting factor for its implementation. Currently in India,
52 viral load testing has been phased in to support patients failing first line ART. In the
53 year 2012, about 4157 viral load tests were performed under National AIDS Control
54 Organisation (NACO).[39] Considering \$19.6 could have been saved per sample by
55
56
57
58
59
60

1
2
3 performing HIV RT assay, the cost saving for these 4157 viral load tests could have
4 amounted to \$ 81,477 if a HIV RT assay had been used.
5
6

7
8 In our cost-comparison analysis we have used a provider perspective (lab service). We
9 acknowledge that this is a narrower perspective than a societal one, which would
10 include patient costs, opportunity costs among other costs. However the purpose of our
11 analysis was to provide information to laboratories in resource constrained settings,
12 often faced with decisions in the face of tight budgets and thus a societal perspective
13 was not considered necessary. A laboratory manager faced with a limited budget
14 would concentrate entirely on costs that have an immediate impact on her/his own
15 budget; this is the perspective adopted in this study.
16
17
18
19

20
21 NACO is now considering taking up the monitoring approach recommended by WHO
22 to diagnose and confirm ART failure. Considering that there currently are 604,987
23 HIV-1 infected individuals receiving first line of ART at 380 centers spread across the
24 country the cost reduction of utilizing HIV RT compared to HIV RNA plasma load can
25 be substantial.[40]
26
27
28
29

30
31 Scaling up ART requires the critical support of HIV-1 viral load monitoring. Evidence
32 from the comparative performance of the HIV RT assay with HIV-1 RNA assays from
33 ours and other studies from India, indicate that the ExaVir Load assay could serve as
34 an affordable alternative to monitor patients on ART.
35
36
37
38
39

40 41 **Acknowledgments**

42
43 The authors would like to thank the HIVIND study team for their outstanding efforts in
44 recruiting and following the study participants and collection of samples. Authors
45 would also like to thank Pravat Nalini Sahoo and Shwetha D Rao, St. John's Research
46 Institute to perform laboratory experiments pertaining to HIV-1 drug resistance and
47 HIV-1 RNA load. We are very much thankful to Staffan Sjö Dahl, Cavid AB for his
48 technical help and support with the ExaVir Load v3 assay. Ujjwal Neogi acknowledges
49 the support received from Karolinska Institutet Research Foundation Grants
50 (2014fobi41250). We also acknowledge the staff at the ART Centre, St. John's
51 Medical College Hospital and KR Hospital, Mysore for their excellent teamwork and
52 patient care and NACO and Karnataka State AIDS Prevention Society (KSAPS) for
53
54
55
56
57
58
59
60

1
2
3 their support. Most importantly, we are ever thankful to the patients for their
4 participation in the study.
5
6
7
8

9 10 **Authors Contribution**

11
12 Conceived the Study: UN ADC CK PA AS. Designed the experiments: SG UN HS
13 ADC CK AS. Performed the experiments: SG RPC. External lab monitoring and
14 interim quality assessment: PA. Analyzed the data: SG UN ADC CK AS. Contributed
15 reagents/materials/analysis tools: CK AS. Contributed to the writing of the manuscript:
16 SG RP UN HS PA ADC CK AS.
17
18
19
20
21
22
23

24 **Competing interests**

25
26 Clas Källander is an employee of Cavid AB, Uppsala, Sweden. All the other authors
27 have declared that no competing interests exist.
28
29
30
31
32

33 **Funding**

34
35 The study was financially supported by a grant under the European Union Framework
36 Program 7 (project no: 222946). The funders had no role in study design, data
37 collection and analysis, decision to publish, or preparation of the manuscript.
38
39
40
41
42

43 **Data sharing statement**

44
45 No additional data available.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Neogi U, Heylen E, Shet A, et al. Long-term efficacy of first line antiretroviral therapy in Indian HIV-1 infected patients: a longitudinal cohort study. *PloS one* 2013;**8**(1):e55421 doi: 10.1371/journal.pone.0055421[published Online First: Epub Date]].
2. Antiretroviral Therapy Cohort C. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. *Lancet* 2008;**372**(9635):293-9 doi: 10.1016/S0140-6736(08)61113-7[published Online First: Epub Date]].
3. Bryant L, Smith N, Keiser P. A Model for Reduced HIV-1 Viral Load Monitoring in Resource-Limited Settings. *Journal of the International Association of Providers of AIDS Care* 2013;**12**(1):67-71 doi: 10.1177/1545109712442007[published Online First: Epub Date]].
4. Crowe S, Turnbull S, Oelrichs R, Dunne A. Monitoring of human immunodeficiency virus infection in resource-constrained countries. *Clin Infect Dis* 2003;**37**(Suppl 1):S25-35 doi: 10.1086/375369[published Online First: Epub Date]].
5. Rawizza HE, Chaplin B, Meloni ST, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. *Clin Infect Dis* 2011;**53**(12):1283-90 doi: 10.1093/cid/cir729[published Online First: Epub Date]].
6. Wilson D, Keiluhu AK, Kogrum S, et al. HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2009;**103**(6):601-6 doi: 10.1016/j.trstmh.2008.11.007[published Online First: Epub Date]].
7. Iqbal HS, Balakrishnan P, Cecelia AJ, et al. Use of an HIV-1 reverse-transcriptase enzyme-activity assay to measure HIV-1 viral load as a potential alternative to nucleic acid-based assay for monitoring antiretroviral therapy in resource-limited settings. *Journal of medical microbiology* 2007;**56**(Pt 12):1611-4 doi: 10.1099/jmm.0.47456-0[published Online First: Epub Date]].
8. Stewart P, Cachafeiro A, Napravnik S, et al. Performance characteristics of the CaviD ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay. *J Clin Virol* 2010;**49**(3):198-204 doi: 10.1016/j.jcv.2010.07.022[published Online First: Epub Date]].
9. Stevens WS, Scott LE, Crowe SM. Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings. *The Journal of infectious diseases* 2010;**201** **Suppl 1**:S16-26 doi: 10.1086/650392[published Online First: Epub Date]].
10. Sivapalasingam S, Wangechi B, Marshed F, et al. Monitoring virologic responses to antiretroviral therapy in HIV-infected adults in Kenya: evaluation of a low-cost viral load assay. *PloS one* 2009;**4**(8):e6828 doi: 10.1371/journal.pone.0006828[published Online First: Epub Date]].
11. Seyoum E, Wolday D, Girma M, et al. Reverse transcriptase activity for quantitation of HIV-1 subtype C in plasma: relation to RNA copy number and CD4 T-cell count. *J Med Virol* 2006;**78**(2):161-8 doi: 10.1002/jmv.20523[published Online First: Epub Date]].
12. Malmsten A, Shao XW, Sjudahl S, et al. Improved HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma. *J Med*

- 1
2
3 Virol 2005;**76**(3):291-6 doi: 10.1002/jmv.20360[published Online First: Epub
4 Date]].
- 5 13. Lombart JP, Vray M, Kafando A, et al. Plasma virion reverse transcriptase activity
6 and heat dissociation-boostered p24 assay for HIV load in Burkina Faso, West
7 Africa. *AIDS (London, England)* 2005;**19**(12):1273-7
- 8 14. Labbett W, Garcia-Diaz A, Fox Z, et al. Comparative evaluation of the ExaVir
9 Load version 3 reverse transcriptase assay for measurement of human
10 immunodeficiency virus type 1 plasma load. *J Clin Microbiol*
11 2009;**47**(10):3266-70 doi: 10.1128/JCM.00715-09[published Online First:
12 Epub Date]].
- 13 15. Jennings C, Fiscus SA, Crowe SM, et al. Comparison of two human
14 immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV
15 RNA assay. *J Clin Microbiol* 2005;**43**(12):5950-6 doi:
16 10.1128/JCM.43.12.5950-5956.2005[published Online First: Epub Date]].
- 17 16. Huang D, Zhuang Y, Zhai S, et al. HIV reverse transcriptase activity assay: a
18 feasible surrogate for HIV viral load measurement in China. *Diagnostic*
19 *microbiology and infectious disease* 2010;**68**(3):208-13 doi:
20 10.1016/j.diagmicrobio.2010.06.007[published Online First: Epub Date]].
- 21 17. Greengrass VL, Turnbull SP, Hocking J, et al. Evaluation of a low cost reverse
22 transcriptase assay for plasma HIV-1 viral load monitoring. *Current HIV*
23 *research* 2005;**3**(2):183-90
- 24 18. Greengrass VL, Plate MM, Steele PM, et al. Evaluation of the Cavid ExaVir Load
25 assay (version 3) for plasma human immunodeficiency virus type 1 load
26 monitoring. *J Clin Microbiol* 2009;**47**(9):3011-3 doi: 10.1128/JCM.00805-
27 09[published Online First: Epub Date]].
- 28 19. Greengrass V, Lohman B, Morris L, et al. Assessment of the low-cost Cavid
29 ExaVir Load assay for monitoring HIV viral load in pediatric and adult
30 patients. *Journal of acquired immune deficiency syndromes (1999)*
31 2009;**52**(3):387-90 doi: 10.1097/QAI.0b013e3181b05f62[published Online
32 First: Epub Date]].
- 33 20. Shao Y, Williamson C. The HIV-1 epidemic: low- to middle-income countries.
34 *Cold Spring Harbor perspectives in medicine* 2012;**2**(3):a007187 doi:
35 10.1101/cshperspect.a007187[published Online First: Epub Date]].
- 36 21. Mine M, Bedi K, Maruta T, et al. Quantitation of human immunodeficiency virus
37 type 1 viral load in plasma using reverse transcriptase activity assay at a district
38 hospital laboratory in Botswana: a decentralization pilot study. *Journal of*
39 *virological methods* 2009;**159**(1):93-7 doi:
40 10.1016/j.jviromet.2009.03.008[published Online First: Epub Date]].
- 41 22. Stevens G, Rekhviashvili N, Scott LE, Gonin R, Stevens W. Evaluation of two
42 commercially available, inexpensive alternative assays used for assessing viral
43 load in a cohort of human immunodeficiency virus type 1 subtype C-infected
44 patients from South Africa. *J Clin Microbiol* 2005;**43**(2):857-61 doi:
45 10.1128/JCM.43.2.857-861.2005[published Online First: Epub Date]].
- 46 23. Shet A, Costa AD, Kumarasamy N, et al. Effect of mobile telephone reminders on
47 treatment outcome in HIV: evidence from a randomised controlled trial in
48 India. *BMJ* 2014;**347**:g5978-g78 doi: 10.1136/bmj.g5978[published Online
49 First: Epub Date]].
- 50 24. NACO, Department of AIDS Control, Ministry of Health and Family Welfare,
51 Annual Report 2012-13 available at
52
53
54
55
56
57
58
59
60

- http://www.nacoonline.org/upload/Publication/Annual_Report/Annual_report_2012-13_English.pdf accessed on 8 July 2013.
25. Neogi U, Prarthana BS, Gupta S, et al. Naturally occurring polymorphisms and primary drug resistance profile among antiretroviral-naive individuals in Bangalore, India. *AIDS research and human retroviruses* 2010;**26**(10):1097-101 doi: 10.1089/aid.2010.0092[published Online First: Epub Date]].
 26. Gupta S, Neogi U, Srinivasa H, Banerjea AC, Shet A. HIV-1 co-receptor tropism in India: increasing proportion of X4-tropism in subtype C strains over two decades. *Journal of acquired immune deficiency syndromes (1999)* 2013 doi: 10.1097/qai.000000000000046[published Online First: Epub Date]].
 27. Neogi U, Bontell I, Shet A, et al. Molecular epidemiology of HIV-1 subtypes in India: origin and evolutionary history of the predominant subtype C. *PloS one* 2012;**7**(6):e39819 doi: 10.1371/journal.pone.0039819[published Online First: Epub Date]].
 28. Neogi U, Gupta S, Palchadhuri R, et al. Limited evolution but increasing trends of primary non-nucleoside reverse transcriptase inhibitor resistance mutations in therapy-naive HIV-1-infected individuals in India. *Antiviral therapy* 2014 doi: 10.3851/imp2769[published Online First: Epub Date]].
 29. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. *PloS one* 2009;**4**(3):e4724 doi: 10.1371/journal.pone.0004724[published Online First: Epub Date]].
 30. Steegen K, Luchters S, De Cabooter N, et al. Evaluation of two commercially available alternatives for HIV-1 viral load testing in resource-limited settings. *Journal of virological methods* 2007;**146**(1-2):178-87 doi: 10.1016/j.jviromet.2007.06.019[published Online First: Epub Date]].
 31. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Geneva, Switzerland. . 2013
 32. Kokkayil P, Kurapati S, Negi N, Vajpayee M. Comparative evaluation of a reverse transcriptase based assay for HIV-1 viral load quantitation in resource limited settings. *Journal of virological methods* 2014;**203**:1-4 doi: 10.1016/j.jviromet.2014.02.021[published Online First: Epub Date]].
 33. Malmsten A, Shao XW, Aperia K, et al. HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma. *J Med Virol* 2003;**71**(3):347-59 doi: 10.1002/jmv.10492[published Online First: Epub Date]].
 34. van Rooijen LB, Greengrass V, Morris LM, et al. Effect of reverse transcriptase inhibitors and mutations on the low-cost Cavid reverse transcriptase viral load assay. *Journal of acquired immune deficiency syndromes (1999)* 2009;**52**(4):527-9 doi: 10.1097/QAI.0b013e3181b9e726[published Online First: Epub Date]].
 35. Napravnik S, Cachafeiro A, Stewart P, Eron JJ, Jr., Fiscus SA. HIV-1 viral load and phenotypic antiretroviral drug resistance assays based on reverse transcriptase activity in comparison to amplification based HIV-1 RNA and genotypic assays. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology* 2010;**47**(1):18-22 doi: 10.1016/j.jcv.2009.10.001[published Online First: Epub Date]].
 36. Shao XW, Malmsten A, Lennerstrand J, et al. Use of HIV-1 reverse transcriptase recovered from human plasma for phenotypic drug susceptibility testing. *AIDS*

- (London, England) 2003;**17**(10):1463-71 doi: 10.1097/01.aids.0000072670.21517.0d[published Online First: Epub Date]].
37. Gerardo Alvarez-Uria JMA, Srinivasulu Reddy, Manoranjan Midde, Praveen K. Naik, N. Raghuprakash Reddy Point of care testing of HIV in children younger than 18 months with three different HIV virological assays. Experience from a district hospital in a resource-limited setting. *Microbiology Research* 2012;**3**(1):e14 doi: 10.4081/mr.2012.e14[published Online First: Epub Date]].
38. Sax PE. Editorial commentary: can we break the habit of routine CD4 monitoring in HIV care? *Clin Infect Dis* 2013;**56**(9):1344-6 doi: 10.1093/cid/cit008[published Online First: Epub Date]].
39. Ataher Q, Portsmouth S, Napolitano LA, et al. The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa. *J Int AIDS Soc* 2012;**15**(1):2
40. Vitoria M, Vella S, Ford N. Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges. *Curr Opin HIV AIDS* 2013;**8**(1):12-8 doi: 10.1097/COH.0b013e32835b8123[published Online First: Epub Date]].

Figure Legends:

Figure 1: Correlation between Abbott m2000rt and ExaVir Load v3 assay for A) all 629 samples showing $r = 0.96$ B) 327 baseline (WK00) samples showing $r = 0.84$ and C) 302 4-weeks post-ART (WK04) samples showing $r = 0.77$.

Figure 2: Bland-Altman plot with 95% CI of limits of agreement between HIV-1 viral loads measured with Abbott Real-Time m2000rt assay and ExaVir Load v3 assay for A) all 629 samples showing a mean bias of 0.22 with 95% limits of agreement ranging from -0.45 to 0.89 B) 327 baseline (WK00) samples showing a mean bias of 0.25 with 95% limits of agreement ranging from -0.39 to 0.89 C) 302 4-weeks post-ART (WK04) samples showing a mean bias of 0.19 with 95% limits of agreement ranging from -0.52 to 0.89.

Figure 1A




Figure 1B




Figure 1C




Figure 1: Correlation between Abbott m2000rt and ExaVir Load v3 assay for A) all 629 samples showing $r = 0.96$ B) 327 baseline (WK00) samples showing $r = 0.84$ and C) 302 4-weeks post-ART (WK04) samples showing $r = 0.77$.
157x243mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60






Figure 2: Bland-Altman plot with 95% CI of limits of agreement between HIV-1 viral loads measured with Abbott Real-Time m2000rt assay and ExaVir Load v3 assay for A) all 629 samples showing a mean bias of 0.22 with 95% limits of agreement ranging from -0.45 to 0.89 B) 327 baseline (WK00) samples showing a mean bias of 0.25 with 95% limits of agreement ranging from -0.39 to 0.89 C) 302 4-weeks post-ART (WK04) samples showing a mean bias of 0.19 with 95% limits of agreement ranging from -0.52 to 0.89. 159x246mm (300 x 300 DPI)